Clinical trials
Gastric Adenocarcinoma clinical trials
Below are recruiting gastric adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 227 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06123338RecruitingPhase 2
Pembrolizumab plus chemo and trastuzumab for HER2+ stomach cancer
This trial tests adding pembrolizumab to standard trastuzumab and chemotherapy for people with HER2-positive stomach or esophageal cancer that can be fully removed with surgery. The goal is to see if this combination improves outcomes before and after surgery.
Boston, MassachusettsAges 18 years+ - NCT05482893RecruitingPhase 1/Phase 2
Study of spevatamig for advanced gastrointestinal cancers
This trial tests a new drug called spevatamig (PT886) alone or with other treatments for advanced stomach, gastric, pancreatic, bile duct, or colorectal cancers. The goal is to see if it helps slow or stop cancer growth.
Duarte, CaliforniaAges 18 years+ - NCT06300879Recruiting
New surgery technique for upper stomach or junction cancer
This study tests a new surgical technique for removing cancer in the upper stomach or where the stomach meets the esophagus. It aims to see if this technique is safe and effective for people with early-stage adenocarcinoma who haven't had other cancer treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07289997RecruitingPhase 2
Combination therapy for advanced AFP-producing gastric cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (apatinib) and a chemotherapy drug (irinotecan hydrochloride) for people with a rare type of advanced stomach cancer called AFP-producing gastric cancer. It is for patients whose cancer did not respond to previous immunotherapy combined with chemotherapy.
Shijiazhuang, HebeiAges 18 years+ - NCT06199895RecruitingPhase 2
Study of paclitaxel for patients with taxane-resistant solid tumors
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
Wuhan, HubeiAges 18 years+ - NCT07689851RecruitingPhase 2
Chemoradiotherapy plus an immunotherapy for advanced gastric cancer
This trial studies a new immunotherapy drug (SHR-1701) combined with standard chemoradiotherapy for people with advanced stomach or esophagus cancer that cannot be surgically removed. The goal is to see if adding this immune treatment helps control the tumor better than standard treatments alone.
Shenzhen, GuangdongAges 18–75 - NCT07552402Recruiting
Oral Paclitaxel Plus Fruquintinib for Advanced Stomach Cancer
This trial tests a combination of two oral drugs (paclitaxel and fruquintinib) for advanced stomach cancer that has already been treated with one round of chemotherapy. The goal is to see if this combination helps control the cancer better than other standard second-line treatments.
Shijiazhuang, HebeiAges 18–75 - NCT06764875RecruitingPhase 3
New drug combo for HER2-positive stomach cancer
This trial tests a new immunotherapy called rilvegostomig combined with standard chemotherapy and a targeted therapy (trastuzumab deruxtecan) for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has not been treated before.
Anchorage, AlaskaAges 18 years+ - NCT06560528RecruitingPhase 2
Drug combo before & after surgery for HER2+ stomach cancer
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT04447352RecruitingPhase 3
HIPEC plus FLOT versus FLOT alone for gastric or GE junction cancer
This trial compares two treatment approaches after your stomach/GE junction cancer has been treated with chemotherapy before surgery: adding a special heated bath into the abdomen (HIPEC) plus continuing the usual surgery plan. It aims to see if adding HIPEC lowers cancer coming back and improves outcomes.
AachenAges 18–75 - NCT06829797RecruitingPhase 2
Iparomlimab and chemotherapy vs chemotherapy alone for stomach cancer
This trial tests whether adding an immunotherapy drug (Iparomlimab and Tuvonralimab, combined as QL1706) to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced stomach or gastroesophageal junction cancer that can be surgically removed.
Jinan, ShandongAges 18–75 - NCT06669663Recruiting
Hypoxia and metabolism in esophageal and stomach cancer
This trial looks at how low oxygen levels (hypoxia) affect the metabolism of esophageal and stomach cancers. It may help doctors understand why some cancers grow or resist treatment, possibly leading to better therapies.
LondonAges 18–90 - NCT03539822RecruitingPhase 1/Phase 2
Cabozantinib and immunotherapy for advanced stomach or bowel cancers
This early-phase study tests a combination of anti-cancer pills and immune-based treatment for people with advanced stomach, esophagus, colorectal, or liver cancer. It aims to shrink tumors and see how safe the treatment is, including whether biopsy testing can help guide future care.
Westwood, KansasAges 18 years+ - NCT07751302Recruiting
Follow-up vs. chemo after surgery for early stomach cancer
This trial compares two approaches after surgery for early-stage stomach or GEJ cancer: close monitoring (follow-up) vs. adjuvant chemotherapy (chemo given after surgery). It aims to see if follow-up alone is as good as chemo for patients with this stage, potentially avoiding chemo side effects.
Xi'an, ShaanxiAges 18 years+ - NCT07362186RecruitingPhase 3
LM-108 with Toripalimab vs Paclitaxel for advanced stomach cancer
This trial tests a new combination of two immunotherapy drugs (LM-108 and Toripalimab) against a standard chemotherapy drug (Paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker called CCR8. It may be an option if you have already tried a first-line therapy and your cancer has progressed or you had side effects from chemotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05494060RecruitingPhase 2
Adjuvant chemo plus immunotherapy for ctDNA-positive stomach cancer
This trial tests whether adding an anti-cancer immune treatment and another targeted drug to standard chemotherapy after surgery can lower the chance of cancer coming back. It is for people whose blood test (ctDNA) shows leftover cancer-related DNA after surgery.
Nanjing, JiangsuAges 18–75 - NCT07176312RecruitingPhase 2
Zanidatamab with pembrolizumab and chemo for HER2+ and PD-L1+ stomach cancer
This trial tests a new combination of targeted therapy (zanidatamab), immunotherapy (pembrolizumab), and chemotherapy for people with HER2-positive and PD-L1-positive advanced stomach or gastroesophageal cancer. It aims to see if this combination is more effective than current treatments.
BerlinAges 18 years+ - NCT06277024Recruiting
Combination therapy for advanced HER2-negative stomach cancer
This trial tests a combination of immunotherapy (candenizumab), a targeted therapy (lenvatinib), and chemotherapy (SOX regimen) for advanced HER2-negative stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination is safe and works better than standard treatments.
Fuzhou, FujianAges 18–75 - NCT06782412RecruitingPhase 2/Phase 3
New imaging test for different cancers using FAPI-PET
This trial is testing a new imaging method called FAPI-PET to see if it can help find and understand tumors better than standard scans. It is for people with newly diagnosed stomach/esophageal cancer, pancreatic cancer, or those with unclear symptoms or scan results.
EdegemAges 18 years+ - NCT03175224RecruitingPhase 2
Test drug APL-101 for lung or other tumors with MET changes
This Phase 2 study tests APL-101 to shrink advanced cancers that have certain MET-related changes, including specific MET mutations, MET gene amplification, or MET fusions. It may help people whose tumors have run out of standard treatment options.
Los Angeles, CaliforniaAges 18 years+ - NCT06047379RecruitingPhase 1/Phase 2
Testing NEO212 for brain tumors and metastases
This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.
Beverly Hills, CaliforniaAges 18 years+ - NCT07829081Recruiting
Watch-and-wait after immunotherapy for early-stage GI cancers
This study looks at whether some patients with early-stage stomach, colon, or rectal cancers that are mismatch repair-deficient (a genetic feature making them more likely to respond to immunotherapy) can safely avoid surgery and instead be monitored closely after treatment with immunotherapy. It aims to confirm if this watch-and-wait approach is as effective and helps patients avoid major operations.
BaselAges 18 years+ - NCT07441785Recruiting
Comparing stomach reconstruction types after upper stomach cancer surgery
This study compares different ways to rebuild the digestive tract after removing the upper part of the stomach for cancer. It aims to find which method works best for eating and quality of life.
MoscowAges 18 years+ - NCT07702292RecruitingPhase 2
68Ga-BED003 PET scan for certain cancers
This trial tests a new PET imaging agent that targets a protein called FAP, which appears in many solid tumors. The goal is to see if this scan can better find and measure cancer in the body.
Bergamo, LombardyAges 18–79
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastric adenocarcinoma?
- Yes. Clin2 currently lists 227 recruiting gastric adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastric adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastric adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Gastric / Gastroesophageal Junction Adenocarcinoma
- Metastatic Gastric Adenocarcinoma
- Locally Advanced Gastric Adenocarcinoma
- Gastric Cancer Adenocarcinoma Metastatic
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Advanced Gastric Adenocarcinoma
- Unresectable Gastric Adenocarcinoma
- AFP Gastric or Gastroesophageal Junction Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.